Spiriva is a prescription drug used to help ease breathing problems caused by COPD and asthma. ... You may be able to get a 90-day supply of Spiriva if approved by your insurance company.

Pulmatrix CEO Robert Clarke said that European regulatory authorities “allow for product registration and eventual marketing based on pharmacokinetic bioequivalence” in COPD drugs.

Spiriva is used to ease breathing difficulties in people with COPD or asthma. Find out what the recommended dosages are, how to take the drug, and more.

SPIRIVA RESPIMAT is not a treatment for sudden asthma symptoms. ... Since its founding in 1885, the company has remained family-owned, ...

The Food and Drug Administration's panel of lung specialists voted 11-1 in favor of new labeling about the benefits of Boehringer Ingelheim's Spiriva Handihaler, which is approved to treat lung ...

Spiriva Handihaler had a market value of $1.5 billion for the 12 months ended May 2021, ... each of which has the potential to be a meaningful contributor to our company's financial performance.

Important Safety Information for SPIRIVA RESPIMAT Do not use SPIRIVA® RESPIMAT® (tiotropium bromide) ... Germany, the company operates globally with approximately 50,000 employees.

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler ...

Spiriva is a promising alternative asthma treatment and some doctors are already using ... The company also "lacked adequate information in this case to understand what the impact would be on ...

SPIRIVA HandiHaler also produced an 11 percent reduction per year in the number of exacerbations experienced by COPD patients (p=0.002), and reduced the risk of exacerbations treated with systemic ...

Adding Spiriva to conventional therapy improves symptoms in patients whose asthma is poorly controlled and gives them more days without breathing problems, researchers reported on Sunday.

India's patent office has revoked the patent of Boehringer Ingelheim on emphysema treatment Spiriva after a challenge from local firm Cipla. | India's patent office has revoked the patent of ...